Chieftain Securities
Home OUR BUSINESS The Team NEWS PORTFOLIO CHATTER CONTACT
HomeOUR BUSINESSThe TeamNEWSPORTFOLIOCHATTERCONTACT
Chieftain Securities
MGC: Ethics Committee Approval Received for Phase II Clinical Trial on Patients Diagnose with COVID-19
Guest User17 April 20202020
Facebook0 Twitter 0 Likes
Previous

CVV: Placement and Share Purchase Plan to Raise up to $1.65M

Guest User15 July 20202020
Next

SAS: Notice of Meeting - Placement to Raise $15m

Guest User26 August 20192019
Chieftain Securities
1202 Hay Street,
West Perth, WA, 6005,
Australia
info@chiefsec.com.au
Hours

Copyright © 2021 Chieftain Securities | All Right Reserved | Images used with Permission. Privacy Policy